comparemela.com

Page 4 - Viatris Company News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Theravance Biopharma Announces Tender Offer For Up To $95 Million Of Its Ordinary Shares

/PRNewswire/ Theravance Biopharma, Inc. ("Theravance Biopharma" or the "Company") (NASDAQ: TBPH) today announced a "modified Dutch auction" tender offer.

New yorkUnited statesTheravance biopharmaGail cohenComputershare trust companyCompany offer to purchaseTheravance biopharma incCompany formCorporate communicationsSecurities exchangePrnewswire theravance biopharma incViatris companyEvercore groupNone of the companyNew york cityMany shares

Theravance Biopharma, Inc Initiates $250 Million Capital Return Program

/PRNewswire/ Theravance Biopharma, Inc. ("Theravance Biopharma" or the "Company") (NASDAQ: TBPH) announced today that its Board of Directors has authorized.

Theravance biopharmaGailb cohenCorporate communicationsPrnewswire theravance biopharma incTheravance biopharma incSecurities exchangeViatris companyOpen market share repurchase planOpen market stock repurchase planInformation regardingTender offer statementTender offerPrivate securities litigation reform actSecurities exchange act

Theravance Biopharma, Inc Reports Second Quarter 2022 Financial Results and Provides Business Update

Highest quarter of YUPELRI® (revefenacin) net sales and profitability to date1: $17.2M Q2 2022 sales up 17% from Q2 2021 (implied 35% share) Ampreloxetine.

Ricke winninghamTheravance biopharmaGailb cohenTheravance biopharma incCompany tender offer statement on scheduleCompany annual report on formDevelopment rd expensesTheravance respiratory companyCorporate communicationsSecurities exchangePrnewswire theravance biopharma incViatris companyWhile viatris incMultiple system atrophyRoyalty pharmaConvertible senior

Theravance Biopharma to Report Second Quarter 2022 Financial Results on August 4, 2022

/PRNewswire/ Theravance Biopharma, Inc. (NASDAQ: TBPH) will report its second quarter 2022 financial results and provide a business update after market.

Theravance biopharmaGailb cohenCorporate communicationsTheravance biopharma incPrnewswire theravance biopharma incViatris company

Theravance Biopharma Announces Tender Offer For Outstanding 3 25% Convertible Senior Notes Due 2023

/PRNewswire/ Theravance Biopharma, Inc. ("Theravance Biopharma" or the "Company") (NASDAQ: TBPH) today announced a tender offer (the "Offer") to purchase.

New yorkUnited statesTheravance biopharmaGail cohenCompany offer to purchaseTheravance biopharma incCompany formCorporate communicationsSecurities exchangePrnewswire theravance biopharma incViatris companyEvercore groupNone of the companyConvertible senior notesConvertible notesNew york city

vimarsana © 2020. All Rights Reserved.